Mr Alex Trafford (University of Manchester, UK) noted that an association between cancer and psoriasis is plausible due to the chronic inflammation in psoriasis patients [1]. Moreover, lifestyle factors like smoking and alcohol consumption are particularly prevalent in patients with psoriasis. Yet, previous studies of cancer risk in people with psoriasis have yielded inconsistent results. To evaluate the possible relationship, Mr Trafford and colleagues aimed to investigate the risk of cancer occurrence in individuals with psoriasis by analysing data from population-based health records from Denmark, England, Israel, and Taiwan. They also wanted to explore whether cancer risk is associated with psoriasis severity. “As we had no direct data, we used systemic therapy as an indicator of moderate-to-severe psoriasis,” he explained.
Individuals with psoriasis from the cohort were matched with up to 6 individuals with no prior record of psoriasis based on a minimum of age, sex, and calendar time. Country-specific risks of cancer overall and site-specific cancers were analysed using Cox proportional hazards models. Patients who had cancer before were excluded from the analysis.
The analysis included 702,062 participants with psoriasis and 4,185,596 matched comparators. Age and sex were similar between countries. Patients in Denmark were older; in Taiwan, they were more likely to be men. In crude models, individuals with psoriasis (pooled HR 1.08; 95% CI 1.04–1.13) and the subgroup with moderate-to-severe psoriasis (pooled HR 1.16; 95% CI 1.04–1.28) had a slightly higher risk of cancer overall.
Further, people with psoriasis had higher risks for the following site-specific cancers: oral cavity, pharynx, oesophagus, liver, pancreas, kidney, bladder, skin (keratinocyte), Hodgkin lymphoma, non-Hodgkin lymphoma, and leukaemia. However, the risk elevation differed between cancer types, from a relatively modest 9% relative risk elevation in pancreas cancer to an almost doubled risk for Hodgkin lymphoma. “The cancer risk was exacerbated in more severe psoriasis. Moreover, additional associations for lung cancer and ovarian cancer were found in these patients,” Mr Trafford said.
In summary, the study established the associated increased risk of developing cancer in psoriasis patients. Associations generally persist, with a more pronounced risk, when limited to people with moderate-to-severe disease. The current study revealed that psoriasis is associated with several cancers, beyond those currently regarded to be linked to the condition. This should be recognised to guide optimal psoriasis care and future research.
- Trafford AM, et al. Psoriasis and the risk of cancer development: pooled population-based cohort studies from Denmark, England, Israel and Taiwan. FC13, Psoriasis from Gene to Clinic 2021, 9–11 December.
Copyright ©2021 Medicom Medical Publishers
© 2023 The Author(s). Published by Medicom Medical Publishers.
User license: Creative Commons Attribution – NonCommercial (CC BY-NC 4.0)
Posted on
Previous Article
« Comorbidity and clinical features of psoriasis vary according to HLA-C*06:02 status Next Article
Gut microbiota of psoriasis patients: less diverse and reduced functionality »
« Comorbidity and clinical features of psoriasis vary according to HLA-C*06:02 status Next Article
Gut microbiota of psoriasis patients: less diverse and reduced functionality »
Table of Contents: PFGC 2021
Featured articles
Letter from the Editor
Guselkumab shows highest drug survival among systemic treatments
Genes in Psoriasis and Psoriatic Arthritis
HLA-C*06:02-positive patients on ustekinumab show higher drug survival in a real-world scenario
Protective factors identified against anti-drug antibody formation to adalimumab in psoriasis
Comorbidity in Psoriasis
Psoriasis associated with a higher cancer risk
Comorbidity and clinical features of psoriasis vary according to HLA-C*06:02 status
Psoriasis patients with cardiovascular comorbidity characterised by high systemic inflammation
Psoriasis Therapy: New Findings
Inhibition of heat shock protein: A novel way to treat psoriasis?
Guselkumab shows highest drug survival among systemic treatments
Tapering biologics: No alarming signs of increased anti-drug antibodies
Intermediate monocytes are possible predictors of response to secukinumab
Gut microbiota of psoriasis patients: less diverse and reduced functionality
COVID-19: What's New
DLQI scores underestimated during lockdowns?
TNF blockers likely beneficial for psoriatic patients with COVID-19
Patients on immunomodulators need 2 COVID-19 vaccinations before seroconversion
Paradoxical Reactions to Biologics
The Yin and Yang of opposing vectors: an explanation for side effects of biologics
Explaining arthropathy development through IL-4 and IL-13 blockade
Best of the Posters
Potential biomarker discovered for treatment response to ustekinumab
TNF inhibitor for immune-mediated inflammatory disease doubles the risk of paradoxical psoriasis
Secukinumab also tolerable in paediatric psoriasis patients
High treatment success with ixekizumab in patients with psoriasis and diabetes
Related Articles
April 19, 2019
Psoriasis and Biologics: The Beat Goes On
February 4, 2020
Lowest risk of infection after therapy with an IL-12/IL-23 blocker
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy